📊 DRMAW Key Takeaways
Is DRMAW a Good Investment? Thesis Analysis
Dermata Therapeutics is a pre-revenue pharmaceutical company with severe financial distress, burning $6.4M in operating cash flow against minimal $161K in revenue. The company is fundamentally unprofitable with negative operating margins exceeding -3600% and deteriorating cash position despite strong liquidity, indicating unsustainable burn rate and high bankruptcy risk without significant capital infusion or commercial success.
Why Buy DRMAW? Key Strengths
- Strong liquidity position with 7.66x current ratio and $4.7M cash on hand
- Massive revenue growth of 239% YoY indicating early commercialization attempts
- Minimal debt burden with 0.00x debt-to-equity ratio providing financial flexibility
DRMAW Investment Risks to Consider
- Severe operating losses of -$6.4M annually with negative margins exceeding -3600%, indicating non-viable business model
- Cash burn rate of -$6.4M in operating cash flow relative to $4.7M cash reserves implies less than 1 year of runway
- Minimal revenue of $161K insufficient to support R&D and operational costs typical in pharmaceutical industry
- Pharmaceutical sector requires successful clinical trials and FDA approval with no indication of pipeline maturity
- High frequency of insider Form 4 filings (14 in 90 days) may signal uncertainty or liquidity management concerns
Key Metrics to Watch
- Operating cash burn rate and months of cash remaining
- Revenue trajectory and path to commercial product profitability
- Clinical trial milestones and regulatory approval progress
- Equity raises and capital adequacy for operations
DRMAW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.66x current ratio provides a solid financial cushion.
DRMAW Profitability Ratios
DRMAW vs Healthcare Sector
How Dermata Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DRMAW Overvalued or Undervalued?
Based on fundamental analysis, Dermata Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DRMAW Balance Sheet & Liquidity
DRMAW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Dermata Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-39.99 indicates the company is currently unprofitable.
DRMAW Growth Metrics (YoY)
DRMAW Capital Allocation
DRMAW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Dermata Therapeutics, Inc. (CIK: 0001853816)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DRMAW
What is the AI rating for DRMAW?
Dermata Therapeutics, Inc. (DRMAW) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DRMAW's key strengths?
Claude: Strong liquidity position with 7.66x current ratio and $4.7M cash on hand. Massive revenue growth of 239% YoY indicating early commercialization attempts.
What are the risks of investing in DRMAW?
Claude: Severe operating losses of -$6.4M annually with negative margins exceeding -3600%, indicating non-viable business model. Cash burn rate of -$6.4M in operating cash flow relative to $4.7M cash reserves implies less than 1 year of runway.
What is DRMAW's revenue and growth?
Dermata Therapeutics, Inc. reported revenue of $161.4K.
Does DRMAW pay dividends?
Dermata Therapeutics, Inc. does not currently pay dividends.
Where can I find DRMAW SEC filings?
Official SEC filings for Dermata Therapeutics, Inc. (CIK: 0001853816) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DRMAW's EPS?
Dermata Therapeutics, Inc. has a diluted EPS of $-6.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DRMAW a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Dermata Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DRMAW stock overvalued or undervalued?
Valuation metrics for DRMAW: ROE of -143.9% (sector avg: 15%), net margin of -3,530.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DRMAW stock in 2026?
Our dual AI analysis gives Dermata Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DRMAW's free cash flow?
Dermata Therapeutics, Inc.'s operating cash flow is $-6.4M, with capital expenditures of N/A. FCF margin is -3,983.9%.
How does DRMAW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,530.5% (avg: 12%), ROE -143.9% (avg: 15%), current ratio 7.66 (avg: 2).